Anaferon (pediatric formulation) reduces the incidence of acute respiratory viral infections in sickly children and children with bronchial asthma and has a positive effect on the course of asthma. The preparation produces an immunomodulating effect (increases initially low IFN-gamma levels and normalizes elevated levels of IL-1beta), stimulates synthesis of IgA and IgG, exhibits cytoprotective activity, and improves local immunity of the upper airways in sickly children.